C 반응성 단백질 검사 시장 규모, 점유율, 동향 분석 보고서 : 어세이 유형별, 검출 범위별, 질환 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

C-Reactive Protein Testing Market Growth & Trends:

The global C-reactive protein testing market size is expected to reach USD 5.66 billion by 2030 and is projected to grow at a CAGR of 0.24% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of C-reactive protein (CRP) testing can be attributed to significant research activities aimed at exploring various applications of testing. These research efforts are further facilitated by the presence of both private and public agencies that provide funding to expedite research in this field. The market is anticipated to witness significant growth owing to advancements in nanotechnological tools. These advancements offer promising opportunities to develop portable bioanalytical assays that possess attributes, such as high specificity, sensitivity, rapid response time, and the ability to perform multiplexing for accurate disease diagnosis and monitoring at the point of care.

These advancements are expected to drive the demand for CRP testing during the forecast period. Furthermore, an increase in strategic deals and developments, as well as higher investments in research and development has fueled the growth. The COVID-19 pandemic has had a considerable impact on the market, as CRP is considered a crucial biomarker for assessing the severity of infection and inflammation. As a result, there is an increased demand for services and products. Leading companies, such as Abbott, provide supportive tools for CRP testing specifically for SARS-CoV-2 infection, further contributing to market growth. Moreover, key players increased focus on product launches and developments in point-of-care CRP tests, which is projected to further fuel the market's growth in the coming years.

For instance, in July 2022, Bloom Diagnostics introduced the Bloom Inflammation Test, a semi-automated testing kit designed for the quantification of CRP levels in the blood. This single-use kit aids in the detection of inflammation within the body. The growth of the marketplace is expected to be further stimulated by the establishment of testing facilities. In June 2021, Trivitron Healthcare unveiled a mobile laboratory for COVID-19 diagnostics, enabling testing services in various regions of India, including rural, urban, and remote areas. This indigenous laboratory offers a range of tests, including CLIA/Elisa tests for inflammatory markers, such as a CRP, IL-6, and D-Dimer, as well as rapid antigen tests, RT-PCR tests, CLIA/Elisa Antibodies Tests IgM and IgG, and others.

North America held the largest revenue share of 39.42% in 2022 and is expected to maintain its share during the forecast period due to the increasing prevalence of cardiovascular diseases, a steady stream of product launches, presence of established market players, technological advancements, and well-developed healthcare infrastructure. Asia Pacific is projected to grow at the fastest CAGR of 0.49% from 2023 to 2030. The COVID-19 pandemic originated in China. Being the potential biomarker for determining the severity of the infection, the demand for CRP testing is expected to increase shortly. Key players operating in the global industry are constantly focusing on product launches and geographical expansion to maintain their presence.

C-Reactive Protein Testing Market Report Highlights:

• Based on assay type, the immunoturbidimetric assay segment held the largest revenue share of 48.5% in 2024. Owing to the introduction of a highly sensitive, automated, and cost-effective immunoturbidimetric assay that offers a wide measuring range for accurately detecting the levels of CRP in samples
• Based on detection ranges, the hs-CRP segment dominated the market in 2024 with a revenue share of approximately 42.80%. The hs-CRP features a broad detection range than that compared to the conventional CRP
• Based on disease area type, the cardiovascular diseases segment dominated the market with the largest market share in 2024 and is anticipated to dominate the market throughout the forecast period. The increase in the prevalence of CVDs is the major factor contributing to the growth of the CRP testing market
• The hospitals end-user segment dominated with a market share of 28.0% in 2024 due to the increased adoption of CRP testing in hospitals, particularly in response to the COVID-19 pandemic. This has led to a higher testing rate and contributed to the segment's growth
• Furthermore, the marketplace is experiencing growth due to the increasing prevalence of chronic heart diseases and cancers. These conditions contribute significantly to the market's expansion as there is a rising demand for CRP testing in the diagnosis, management, and monitoring of these diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Assay Type
  • 1.2.2. Detection Range
  • 1.2.3. Disease Type
  • 1.2.4. End Use
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. C-Reactive Protein Testing Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Rising incidence of chronic and infectious diseases
    • 3.3.1.2. Increasing demand for point-of-care diagnostics
    • 3.3.1.3. Growing demand for portable and automated C-reactive proteins
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Lower detection limit
    • 3.3.2.2. Limitations associated with C-reactive protein techniques
• 3.4. C-Reactive Protein Testing Market Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. C-Reactive Protein Testing Market: Assay Type Estimates & Trend Analysis

• 4.1. C-reactive Protein (CRP) Testing Market: Assay Type Movement Analysis
• 4.2. Immunoturbidimetric Assay
  • 4.2.1. Immunoturbidimetric Assay Market, 2018 - 2030 (USD Million)
• 4.3. ELISA
  • 4.3.1. ELISA Market, 2018 - 2030 (USD Million)
  • 4.3.2. Clinical ELISA
    • 4.3.2.1. Clinical ELISA Market, 2018 - 2030 (USD Million)
  • 4.3.3. Nonclinical ELISA
    • 4.3.3.1. Nonclinical ELISA Market, 2018 - 2030 (USD Million)
• 4.4. Chemiluminescence Immunoassay
  • 4.4.1. Chemiluminescence Immunoassay Market, 2018 - 2030 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. C-Reactive Protein Testing Market: Detection Range Estimates & Trend Analysis

• 5.1. C-reactive Protein (CRP) Testing Market: Detection Range Movement Analysis
• 5.2. High Sensitivity C-reactive Protein (hs-CRP)
  • 5.2.1. High Sensitivity C-reactive Protein (hs-CRP) Market, 2018 - 2030 (USD Million)
• 5.3. Conventional CRP
  • 5.3.1. Conventional CRP Market, 2018 - 2030 (USD Million)
• 5.4. Cardiac CRP (cCRP)
  • 5.4.1. Cardiac CRP (CCRP) Market, 2018 - 2030 (USD Million)

Chapter 6. C-Reactive Protein Testing Market Disease Area Estimates & Trend Analysis

• 6.1. C-reactive Protein (CRP) Testing Market: Disease Area Movement Analysis
• 6.2. Cardiovascular Diseases
  • 6.2.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
• 6.3. Cancer
  • 6.3.1. Cancer Market, 2018 - 2030 (USD Million)
• 6.4. Rheumatoid Arthritis
  • 6.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
• 6.5. Inflammatory Bowel Disease
  • 6.5.1. Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
• 6.6. Endometriosis
  • 6.6.1. Endometriosis Market, 2018 - 2030 (USD Million)
• 6.7. Lupus
  • 6.7.1. Lupus Market, 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. C-Reactive Protein Testing Market End Use Estimates & Trend Analysis

• 7.1. C-reactive Protein (CRP) Testing Market: End-use Movement Analysis
• 7.2. Clinics
  • 7.2.1. Clinics Market, 2018 - 2030 (USD Million)
  • 7.2.2. Clinics, by entity
    • 7.2.2.1. Physician offices
      • 7.2.2.1.1. Physician Offices Market, 2018 - 2030 (USD Million)
    • 7.2.2.2. Small clinics
      • 7.2.2.2.1. Small Clinics Market, 2018 - 2030 (USD Million)
    • 7.2.2.3. Others
      • 7.2.2.3.1. Others Market, 2018 - 2030 (USD Million)
  • 7.2.3. Clinics, by setting
    • 7.2.3.1. Urban setting
      • 7.2.3.1.1. Urban Setting Market, 2018 - 2030 (USD Million)
    • 7.2.3.2. Rural settings
      • 7.2.3.2.1. Rural Settings Market, 2018 - 2030 (USD Million)
• 7.3. Hospitals
  • 7.3.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.3.2. Urban setting
    • 7.3.2.1. Urban Setting Market, 2018 - 2030 (USD Million)
  • 7.3.3. Rural settings
    • 7.3.3.1. Rural Settings Market, 2018 - 2030 (USD Million)
• 7.4. Laboratories
  • 7.4.1. Laboratories Market, 2018 - 2030 (USD Million)
  • 7.4.2. Urban setting
    • 7.4.2.1. Urban Setting Market, 2018 - 2030 (USD Million)
  • 7.4.3. Rural settings
    • 7.4.3.1. Rural Settings Market, 2018 - 2030 (USD Million)
• 7.5. Assisted Living Healthcare Facilities
  • 7.5.1. Assisted Living Healthcare Facilities Market, 2018 - 2030 (USD Million)
  • 7.5.2. Urban setting
    • 7.5.2.1. Urban Setting Market, 2018 - 2030 (USD Million)
  • 7.5.3. Rural settings
    • 7.5.3.1. Rural Settings Market, 2018 - 2030 (USD Million)
• 7.6. Home
  • 7.6.1. Home Market, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. C-Reactive Protein Testing Market: Regional Estimates & Trend Analysis

• 8.1. C-Reactive Protein Testing Market Share, By Region, 2024 & 2030, USD Million
• 8.2. North America
  • 8.2.1. North America C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Target Disease Prevalence
    • 8.2.2.3. Competitive Scenario
    • 8.2.2.4. Regulatory Framework
    • 8.2.2.5. Reimbursement Scenario
    • 8.2.2.6. U.S. C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. Canada C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Target Disease Prevalence
    • 8.2.4.3. Competitive Scenario
    • 8.2.4.4. Regulatory Framework
    • 8.2.4.5. Reimbursement Scenario
    • 8.2.4.6. Mexico C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. Reimbursement Scenario
    • 8.3.2.6. UK C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. Germany C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. France C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. Italy C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Spain C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Denmark C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Sweden C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Norway C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Reimbursement Scenario
    • 8.4.2.6. Japan C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. China C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. India C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. Australia C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. South Korea
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. South Korea C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Thailand C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Reimbursement Scenario
    • 8.5.2.6. Brazil C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Argentina C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Reimbursement Scenario
    • 8.6.2.6. South Africa C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. Saudi Arabia C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. UAE C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. Kuwait C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
• 9.5. Abbott
  • 9.5.1. Participant's Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Developments/ Strategic Initiatives
• 9.6. Siemens Healthineers AG
  • 9.6.1. Participant's Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Developments/ Strategic Initiatives
• 9.7. Danaher Corporation
  • 9.7.1. Participant's Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Developments/ Strategic Initiatives
• 9.8. Quest Diagnostics
  • 9.8.1. Participant's Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Developments/ Strategic Initiatives
• 9.9. Siemens Healthineers AG
  • 9.9.1. Participant's Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Developments/ Strategic Initiatives
• 9.10. Abbott
  • 9.10.1. Participant's Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Developments/ Strategic Initiatives
• 9.11. Merck KGaAA
  • 9.11.1. Participant's Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Developments/ Strategic Initiatives
• 9.12. Zoetis
  • 9.12.1. Participant's Overview
  • 9.12.2. Financial Performance
  • 9.12.3. Product Benchmarking
  • 9.12.4. Recent Developments/ Strategic Initiatives
• 9.13. F. Hoffmann-La Roche AG
  • 9.13.1. Participant's Overview
  • 9.13.2. Financial Performance
  • 9.13.3. Product Benchmarking
  • 9.13.4. Recent Developments/ Strategic Initiatives
• 9.14. Ortho Clinical Diagnostics
  • 9.14.1. Participant's Overview
  • 9.14.2. Financial Performance
  • 9.14.3. Product Benchmarking
  • 9.14.4. Recent Developments/ Strategic Initiatives
• 9.15. Thermo Fisher Scientific, Inc.
  • 9.15.1. Participant's Overview
  • 9.15.2. Financial Performance
  • 9.15.3. Product Benchmarking
  • 9.15.4. Recent Developments/ Strategic Initiatives
• 9.16. HORIBA, Ltd
  • 9.16.1. Participant's Overview
  • 9.16.2. Financial Performance
  • 9.16.3. Product Benchmarking
  • 9.16.4. Recent Developments/ Strategic Initiatives
• 9.17. Randox Laboratories Ltd.
  • 9.17.1. Participant's Overview
  • 9.17.2. Financial Performance
  • 9.17.3. Product Benchmarking
  • 9.17.4. Recent Developments/ Strategic Initiatives
• 9.18. Boditech Med, Inc.
  • 9.18.1. Participant's Overview
  • 9.18.2. Financial Performance
  • 9.18.3. Product Benchmarking
  • 9.18.4. Recent Developments/ Strategic Initiatives
• 9.19. Aidian
  • 9.19.1. Participant's Overview
  • 9.19.2. Financial Performance
  • 9.19.3. Product Benchmarking
  • 9.19.4. Recent Developments/ Strategic Initiatives